A question at the bedside. An answer you can defend.
Fast, referenced, bedside-ready answers grounded in the guidelines, formularies and disease patterns that matter here. For physicians, residents and students.
58-year-old, T2DM with CKD (eGFR 38) — safest add-on to metformin?
An SGLT2 inhibitor is preferred at this eGFR, with dose review below 30[1]. Avoid glimepiride dose escalation given hypoglycaemia risk in CKD[2].
- Check eGFR before initiation and at review.
- NLEM lists generic options — cost noted per fill.
Representative answer · not medical advice
A question at the bedside
Type or speak a clinical question in plain language — a diagnosis to narrow, a dose to verify, a regimen to compare.
Answers with citations
Responses pull from Indian guidelines, the NLEM formulary and peer-reviewed evidence — every claim linked to a source.
Ready for the next patient
Save decisions to a case, share with a colleague, or move on — in seconds, not a browser tab deep dive.
58-year-old, T2DM with CKD (eGFR 38) — safest add-on to metformin?
An SGLT2 inhibitor is preferred at this eGFR, with dose review below 30[1]. Avoid glimepiride dose escalation given hypoglycaemia risk in CKD[2].
- Check eGFR before initiation and at review.
- NLEM lists generic options — cost noted per fill.
Built so you can check its work
Direct answer first
The recommendation up top, in two or three sentences — takeaways and detail below it.
Every claim cited
Inline markers resolve to the exact source passage: guideline page, review, or formulary entry.
India-first ranking
ICMR and national guidance outrank international sources; the hierarchy is visible, not implied.
Honest uncertainty
Conflicting guidelines are surfaced side by side. Weak evidence gets a warning, not a confident synthesis.
Physicians
Verify a dose, narrow a differential or check the latest guideline position between patients — with sources you can defend on rounds.
Residents
Answers structured for presentations: direct answer, key takeaways, citations. Save to a case and share with your unit.
Students
Learn the way you will practice — from the guidelines used in Indian wards. Exam-ready context for NEET PG, FMGE and university finals.
The right answer here isn’t always the textbook answer
Global tools default to another country’s formularies, payer logic and disease prevalence. EvidenceFirst ranks Indian guidance first and keeps the hierarchy visible — so you always know whose recommendation you are reading, and why it was ranked above the alternatives.
How we rank evidence- 01ICMR & national guidelines
- 02NHA · CDSCO · NLEM formulary
- 03WHO guidance
- 04NICE · CDC · specialty societies
- 05Systematic reviews & meta-analyses
- 06RCTs · observational evidence
No patient data
A reference tool, not an EMR. No patient records, no scribing, nothing to leak.
Clinician accounts
Sign in with a work email; medical-council verification is rolling out across the platform.
Auditable sources
Every answer decomposes into sources you can open, read and disagree with.
Built by the team behind India’s AI medical-learning companion — used by students across India’s medical colleges. EvidenceFirst brings the same evidence discipline to clinical practice.
What is EvidenceFirst?
A clinical search engine for Indian doctors. Ask a question in plain language and get a structured, referenced answer — direct answer, key takeaways and citations that open the underlying source — in seconds.
Who can use it?
Physicians, residents and medical students. Create a free account with your work email — medical-council verification is rolling out and may be requested for full access.
Is it live?
Yes — EvidenceFirst is live. Create a free account and ask your first question in under a minute.
Is it free?
Free for clinicians and students during rollout. Pricing will be announced before anything changes — no surprise paywalls.
Ready for the ward round.
EvidenceFirst is live. Create a free account with your work email and ask your first question in under a minute.
For physicians, residents and students · Free during rollout